Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
865854-05-3
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Alzheimer's_disease
gptkb:progressive_supranuclear_palsy |
| gptkbp:effect |
inhibits glycogen synthase kinase-3
|
| gptkbp:hasMolecularFormula |
C19H14N4O2S2
|
| gptkbp:hasSMILES |
C1=CC(=C(C=C1C2=NC(=O)SC2=O)Cl)Cl.C1=CC(=C(C=C1)Cl)Cl
|
| https://www.w3.org/2000/01/rdf-schema#label |
tideglusib
|
| gptkbp:IUPACName |
3-[(2,4-dichlorophenyl)methylene]-5-(5-nitro-1,3-thiazol-2-yl)thiazolidine-2,4-dione
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
GSK-3 inhibitor
|
| gptkbp:molecularWeight |
410.47 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2103837
11364421 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
fatigue
headache gastrointestinal symptoms |
| gptkbp:studiedBy |
tooth repair
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:bfsParent |
gptkb:Janus_kinases
gptkb:Noscira |
| gptkbp:bfsLayer |
8
|